UW Carbone Cancer Center - Cancer Connect
Welcome,         Profile    Billing    Logout  
 26 Trials 
61 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Connect, Cancer
NCT03096418: Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

Recruiting
4
50
US
Paclitaxel, Taxol
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Neoplasm Female
06/26
06/26
ROCKnrol-1, NCT06143891: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

Recruiting
3
260
Europe, Canada, US, RoW
Belumosudil, SAR445761/ KD025, REZUROCK, Placebo, Prednisone, Prednisolone
Sanofi
Chronic Graft Versus Host Disease
09/28
09/28
NCI-2018-00466, NCT03302156: PSMA PET and MRI in Gynecological Cancers

Terminated
2
15
US
PSMA-based 18F-DCFPyL PET tracer, PSMA
University of Wisconsin, Madison
Gynecologic Cancer
01/20
01/20
SMILE, NCT04738292: Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The Study)

Terminated
2
11
US
Onapristone, Fulvestrant, Fulvestrant Injection
University of Wisconsin, Madison, Context Therapeutics Inc.
ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
04/23
05/23
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
NCI-2018-02551, NCT03725761: Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

Active, not recruiting
2
31
US
Sacituzumab Govitecan, IMMU-132
University of Wisconsin, Madison, National Cancer Institute (NCI), Gilead Sciences
Prostate Cancer
04/24
04/25
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

Hourglass Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
Checkmark From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
Checkmark Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019
Recruiting
2
340
Europe, US
RP1, nivolumab, Opdivo
Replimune Inc., Bristol-Myers Squibb
Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
12/25
12/28
NCT03943901: Split-Dose R-CHOP for Older Adults With DLBCL

Active, not recruiting
2
26
US
Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Prednisone, Pegfilgrastim, filgrastim
University of Wisconsin, Madison, Medical College of Wisconsin
Diffuse Large B Cell Lymphoma, DLBCL, Cancer
02/25
02/27
BTCRC LUN20-462, NCT04919382: Temozolomide and Atezolizumab as Second or Third Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

Recruiting
2
56
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
Dwight Owen, Genentech, Inc.
Extensive Stage Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
12/25
12/26
DisTinGuish, NCT04363801: A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Hourglass Oct 2023 - Mar 2024 : Q4'23/Q1'24 - Initial ORR data from DisTinGuish trial for 2L gastric cancer
Oct 2023 - Dec 2023: Initial data from part C of DisTinGuish trial in combination with tislelizumab for 1L gastric cancer
Checkmark Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Nov 2022 - Nov 2022: Updated data from part B of DisTinGuish trial in combination with tislelizumab for 2L gastric cancer
Checkmark ORR, PFS and OS data from DisTinGuish trial in combination with tislelizumab for gastroesophageal junction cancer or gastric cancer
More
Active, not recruiting
2
232
Europe, US, RoW
DKN-01 300mg, DKN-01 600mg, DKN-01 400mg, Tislelizumab 200mg, Tislelizumab 400mg, Oxaliplatin, Capecitabine 1000mg/ m2 BID, Xeloda, Leucovorin Calcium, Folinic acid, Fluorouracil
Leap Therapeutics, Inc., BeiGene
Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer
06/25
12/25
NCT04587128: Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Recruiting
2
71
US
Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab
University of Wisconsin, Madison, Doris Duke Charitable Foundation
Metastatic Colorectal Cancer
10/25
10/25
NCT05846646: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligometastatic NSCLC and RCC

Terminated
2
6
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligometastatic Disease
09/24
09/24
NCT05846659: Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies

Terminated
2
16
US
IMSA101, Immune checkpoint inhibitor, pembrolizumab, nivolumab, PULSAR
ImmuneSensor Therapeutics Inc.
Oligoprogressive
11/24
11/24
NCT01743950: A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

Terminated
2
49
US
Bevacizumab, PRDR, re-irradiation
University of Wisconsin, Madison, Genentech, Inc., National Cancer Institute (NCI)
Glioma
12/24
12/24
NCI-2019-07966, NCT04150640: Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma

Recruiting
2
52
US
Nal-IRI, liposomal irinotecan, Oxaliplatin, 5-FU, Fluorouracil, Trastuzumab, Pembrolizumab, Nivolumab
University of Wisconsin, Madison, Ipsen
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
12/25
12/26
NCT05988918: Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Recruiting
2
66
US
ESK981, CEP-11981
University of Michigan Rogel Cancer Center
Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Carcinoma, Gastrointestinal Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Carcinoma, Neuroendocrine Prostate Carcinoma
04/27
04/29
NCT05109494: Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

Recruiting
2
30
US
Conventional Fractionated, Hypofractionated
University of Wisconsin, Madison
Soft Tissue Sarcoma
11/26
11/26
MAPBI, NCT03936478: Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer

Recruiting
2
30
US
MRIdian Radiation Treatment Unit
University of Wisconsin, Madison
Breast Cancer, DCIS, LCIS
01/27
01/31
BTCRC-BRE18-337, NCT03911973: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Active, not recruiting
1/2
37
US
Gedatolisib, Talazoparib
Kari Wisinski, Pfizer, Celcuity Inc
TNBC - Triple-Negative Breast Cancer
07/24
07/24
NCT03090165: Ribociclib and Bicalutamide in AR+ TNBC

Recruiting
1/2
37
US
ribociclib, LEE011, Bicalutamide
Kari Wisinski, Novartis, Big Ten Cancer Research Consortium, University of Wisconsin, Madison
Triple Negative Breast Cancer
09/25
09/25
NCT05230810: Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Recruiting
1/2
40
US
Alpelisib, Piqray, Tucatinib, Tukysa, Fulvestrant, Faslodex,
Criterium, Inc., Novartis, Seagen Inc.
HER2-positive Metastatic Breast Cancer
08/24
06/25
NCT04989946: Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Recruiting
1/2
60
US
Degarelix, pTVG-AR, Nivolumab, Opdivo, Cemiplimab, Libtavo, Fianlimab, REGN3767, FLT PET/CT, 3'-Deoxy-3'-[18F]Fluorothymidine (FLT) positron emission tomography (PET) /computed tomography (CT)
University of Wisconsin, Madison, Madison Vaccines, Inc, United States Department of Defense, Regeneron Pharmaceuticals, Bristol-Myers Squibb, National Cancer Institute (NCI)
Prostate Cancer
12/26
12/28
NCT05655312: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Recruiting
1/2
264
US
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Perspective Therapeutics
Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
12/27
12/29
NCT02508038: Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

Recruiting
1
22
US
TCRαβ+/CD19+ depleted Haploidentical HSCT, Zoledronate, Zoledronic Acid, Zometa
University of Wisconsin, Madison
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Rhabdomyosarcoma, Ewing Sarcoma, Primitive Neuroectodermal Tumor, Osteosarcoma, Neuroblastoma
12/25
12/26
NCT03232164: PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer

Completed
1
126
US
18F-DCFPyL PET
University of Wisconsin, Madison
Prostate Cancer, Prostate Neoplasm
11/24
11/24
NCT06392711: Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

Recruiting
1
36
US
Mesenchymal Stromal Cells (MSC) Dose Level 0, Mesenchymal Stromal Cells (MSC) Dose Level 1
University of Wisconsin, Madison
Xerostomia, Graft-versus-host-disease, Sjogren's Disease
11/28
11/28
NCT04174352: FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

Recruiting
1
12
US
Tamoxifen, FES PET/CT
University of Wisconsin, Madison
ERα+ Breast Cancer, ESR1 Gene Mutation
12/25
12/26
CUE-102-01, NCT05360680: A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Active, not recruiting
1
52
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
12/24
12/26
NCT04020276: OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases

Suspended
1
48
US
SBRT
University of Wisconsin, Madison
Liver Metastases, Stereotactic Body Radiation Therapy, MRI-guided Treatment
02/25
02/25
PARPAML, NCT05101551: Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Recruiting
1
34
US
Talazoparib, Talzenna, Topotecan, Hycamtin, Gemcitabine, Gemzar, Infugem
Norman J. Lacayo, Gateway for Cancer Research
Acute Myeloid Leukemia
03/26
03/26
NCT05568680: SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Recruiting
1
42
US
SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR
Verismo Therapeutics
Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant
12/27
12/27
NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Active, not recruiting
1
54
Europe, US, RoW
KIN-3248
Kinnate Biopharma
Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
06/26
09/26
LONCA, NCT05270057: Loncastuximab Tesirine in Combination with DA-EPOCH-R in Patients with Previously Untreated Aggressive B-cell Lymphoid Malignancies

Recruiting
1
33
US
Etoposide, Etopophos, Toposar, Vepesid, Doxorubicin, Lipodox, Lipodox 50, Doxil, Adriamycin, Rubex, Cyclophosphamide, Cytoxan, Neosar, Endoxan, Procytox, Revimmune, Rituximab, Rituxan, MabThera, Vincristine, Oncovin, Vincasar, Marqibo, Leurocristine, Prednisone, Deltasone, Orasone, Meticorten, Liquid Pred, Loncastuximab Tesirine 0.075 mg/kg by IV, Zynlonta, ADCT-402, loncastuximab tesirine-lpyl, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
Medical College of Wisconsin
B-cell Lymphoma, Burkitt Lymphoma
05/26
05/26
NCT05477823: Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

Recruiting
1
30
US
External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy, Positron emission tomography (PET)/magnetic resonance imaging (MRI)
University of Wisconsin, Madison
Prostate Cancer
08/27
08/27
NCT05820711: Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy

Recruiting
1
30
US
MSC
University of Wisconsin, Madison, National Institute of Dental and Craniofacial Research (NIDCR)
Head and Neck Cancer, Xerostomia
03/26
03/26
ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting
1
120
Japan, US, RoW
EO-3021
Elevation Oncology
Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
09/28
12/28
NCT05132478: The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer

Completed
N/A
126
US
Emotionally Supportive Video, Standard Video
University of Wisconsin, Madison, National Cancer Institute (NCI), University of Michigan
Thyroid Cancer, Thyroid Nodule, Benign Thyroid Nodule
02/23
02/23
NCT05094102: Intraoperative Evaluation of Axillary Lymphatics

Completed
N/A
9
US
OnLume Imaging System, Indocyanine green, ICG
University of Wisconsin, Madison, National Institutes of Health (NIH), OnLume Inc., National Cancer Institute (NCI)
Lymphedema, Surgery, Breast Cancer
04/23
04/23
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

Terminated
N/A
5
US
Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer, Breast Neoplasms
02/24
02/24
NCT05647564: PET/CT Characterization of Treatment Resistance

Recruiting
N/A
20
US
F-fluorodeoxyglucose positron emission tomography (FDG PET), prostate-specific membrane antigen positron emission tomography (PSMA PET)
University of Wisconsin, Madison
Prostate Cancer
03/25
03/27
NCT06701201: A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

Not yet recruiting
N/A
60
US
SynKIR-110, SynKIR-310
Verismo Therapeutics
Cancer
02/42
02/42
NCT06608511: Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

Recruiting
N/A
20
US
Blood draw for the laboratory assessment
University of Wisconsin, Madison, National Center for Advancing Translational Sciences (NCATS)
Skin Cancer, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin, Basal Cell Carcinoma of Skin, Site Unspecified, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
12/26
12/26
MACS, NCT06472726: Mental Health App for Cancer Survivors Study

Recruiting
N/A
30
US
IONA Mind app
University of Wisconsin, Madison, National Cancer Institute (NCI)
Head and Neck Cancer, Head and Neck Cancers, Depression
07/25
07/25
NCT05609435: Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer

Active, not recruiting
N/A
104
US
REASSURE
University of Wisconsin, Madison, National Cancer Institute (NCI)
Breast Cancer
11/25
11/25
NCT03023202: UWCCC Molecular Tumor Board Registry

Recruiting
N/A
5000
US
PMMTB (Precision Medicine Molecular Tumor Board)
University of Wisconsin, Madison, National Cancer Institute (NCI)
Hematologic Neoplasms, Solid Neoplasm
03/27
03/27
NCT05175092: Living Donor Liver Transplantation for CRC Liver Metastases

Withdrawn
N/A
50
US
Living Donor Liver Transplantation, LDLT
University of Wisconsin, Madison
Liver Metastasis Colon Cancer
12/30
12/30
Ma, Vincent T
NCT03712605: Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Hourglass Jan 2023 - Dec 2023 : Results for stage I-III MCC that has been completely removed by surgery
Active, not recruiting
3
280
US
Best Practice, standard of care, standard therapy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
12/25
12/25
NCT05111574: Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

Recruiting
2
99
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Placebo Administration, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Mucosal Melanoma of the Urinary System, Nasopharyngeal Melanoma, Oral Cavity Mucosal Melanoma, Penile Mucosal Melanoma, Rectal Melanoma, Recurrent Mucosal Melanoma, Sinonasal Mucosal Melanoma, Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Urethral Melanoma, Vaginal Melanoma, Vulvar Melanoma
12/25
12/25
KEYNOTE-C86, NCT04993677 / 2021-002037-42: A Study of SEA-CD40 Given With Other Drugs in Cancers

Active, not recruiting
2
77
Europe, Canada, US
SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed, Alimta, carboplatin, Paraplatin
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Carcinoma, Non-Small- Cell Lung
01/24
10/25
MATISSE, NCT05742607 / 2022-001903-42: IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer

Recruiting
2
70
Europe, US
IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy
Innate Pharma, Innate Pharma SA
Non Small Cell Lung Cancer
06/25
09/26
NCT04511013: A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Recruiting
2
112
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Encorafenib, Braftovi, LGX 818, LGX-818, LGX818, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
SWOG Cancer Research Network, National Cancer Institute (NCI)
Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
06/27
06/27
NCT05655312: MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Recruiting
1/2
264
US
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Perspective Therapeutics
Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
12/27
12/29
IMM1104-101, NCT05585320: A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Hourglass Nov 2024 - Dec 2024 : Initial data from at least one additional arm of the Phase 2a portion
Recruiting
1/2
210
US
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104, IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + mGnP, IMM-1-104 + modified FOLFIRINOX (Treatment Group C), IMM-1-104 + mFFX
Immuneering Corporation
Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC)
06/26
06/27
CFT1946-1101, NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
NCT05130255: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Recruiting
1
60
US
GD2-SADA:177Lu-DOTA Complex, two-step radioimmunotherapy
Y-mAbs Therapeutics
SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
03/27
04/27
NCT04137900: Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Recruiting
1
499
US
TAB004, JS004, Toripalimab, TAB001, JS001
TopAlliance Biosciences, Shanghai Junshi Bioscience Co., Ltd., CTI Clinical Trial and Consulting Services
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
03/26
03/26
NCT06199713: Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Recruiting
N/A
24
US
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography, 18F-FDG PET/CT
University of Wisconsin, Madison
Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
01/26
01/29
NCT06608511: Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers

Recruiting
N/A
20
US
Blood draw for the laboratory assessment
University of Wisconsin, Madison, National Center for Advancing Translational Sciences (NCATS)
Skin Cancer, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin, Basal Cell Carcinoma of Skin, Site Unspecified, Cutaneous Squamous Cell Carcinoma (CSCC), Merkel Cell Carcinoma of Skin
12/26
12/26
Li, Jenny
ELVCAP-002-01, NCT05980416: Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Recruiting
1
120
Japan, US, RoW
EO-3021
Elevation Oncology
Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
09/28
12/28

Download Options